Rigel Pharmaceuticals (RIGL) Cash & Equivalents (2010 - 2026)
Rigel Pharmaceuticals (RIGL) posted quarterly Cash & Equivalents of $24.4 million for Q1 2026, down 46.62% year-over-year from $45.7 million in Q1 2025, and down 39.84% quarter-over-quarter from $40.6 million in Q4 2025.
Rigel Pharmaceuticals (RIGL) Cash & Equivalents (2010 - 2026) Analysis & Trends
Rigel Pharmaceuticals' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $24.4 million for Q1 2026.
- In Q1 2026, Cash & Equivalents fell 46.62% year-over-year to $24.4 million; the TTM figure through Mar 2026 stood at $24.4 million (down 46.62% YoY), while the FY2025 annual figure was $40.6 million, down 28.49% from the prior year.
- Cash & Equivalents for Q1 2026 stood at $24.4 million, down from $40.6 million in the prior quarter.
- The five-year high for Cash & Equivalents was $56.7 million in Q4 2024, with the low at $24.4 million in Q1 2026.
- The 5-year median for Cash & Equivalents is $40.3 million (2023), against an average of $38.6 million.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents plunged 67.93% in 2022, then surged 79.45% in 2023.
- Rigel Pharmaceuticals' Cash & Equivalents stood at $24.5 million in 2022, then jumped by 34.04% to $32.8 million in 2023, then jumped by 73.08% to $56.7 million in 2024, then retreated by 28.49% to $40.6 million in 2025, then tumbled by 39.84% to $24.4 million in 2026.
- Business Quant data shows RIGL's Cash & Equivalents at $24.4 million in Q1 2026, $40.6 million in Q4 2025, and $48.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Rigel Pharmaceuticals | 795.39 Mn | 700.06 Mn | 70.18 Mn | 60.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.82 Mn |
| Mar 31, 2026 | 24.41 Mn |
| Dec 31, 2025 | 40.58 Mn |
| Sep 30, 2025 | 48.53 Mn |
| Jun 30, 2025 | 53.41 Mn |
| Mar 31, 2025 | 45.73 Mn |
| Dec 31, 2024 | 56.75 Mn |
| Sep 30, 2024 | 51.69 Mn |
| Jun 30, 2024 | 36.05 Mn |
| Mar 31, 2024 | 25.57 Mn |
| Dec 31, 2023 | 32.79 Mn |
| Sep 30, 2023 | 45.41 Mn |
| Jun 30, 2023 | 48.81 Mn |
| Mar 31, 2023 | 40.29 Mn |
| Dec 31, 2022 | 24.46 Mn |
| Sep 30, 2022 | 29.87 Mn |
| Jun 30, 2022 | 27.20 Mn |
| Mar 31, 2022 | 24.68 Mn |
| Dec 31, 2021 | 18.89 Mn |
| Sep 30, 2021 | 30.40 Mn |